Pancreatic Cancer

BioNTech SE (NASDAQ: BNTX) announced initial data from the Phase 1 study of mRNA-based individualized neoantigen-specific immunotherapy (iNeST), autogene cevumeran. The study assesses cevumeran combined with Tecentriq (atezolizumab) and chemotherapy in patients with resected...

The FDA has lifted the clinical hold on AIM ImmunoTech Inc's (NYSE: AIM) investigational new drug (IND) application for a Phase 2 study of Ampligen for locally advanced pancreatic cancer (AMP-270). The AMP-270 clinical trial's primary objective compares the efficacy of...

AIM ImmunoTech Inc (NYSE: AIM) announced the publication of positive data from a single-center named patient program treating advanced and metastatic pancreatic cancer patients.  The study found that the median overall survival in the Ampligen group was 19 months, compared to a...

Amgen Inc (NASDAQ: AMGN) announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in KRAS G12C-mutated advanced pancreatic cancer patients who received Lumakras (sotorasib).  The data will be presented at the American Society of...

PharmaCyte Biotech Inc (NASDAQ: PMCB) updated its activities to lift the FDA's clinical hold on PharmaCyte's treatment for locally advanced, inoperable pancreatic cancer (LAPC).  After submitting an initial Investigational New Drug Application (IND), the FDA requested...

Nanobiotix (NASDAQ: NBTX) has announced the publication of a peer-reviewed case study in Clinical and Translational Radiation Oncology.  The case study reports on the first patient treatment experience with potential first-in-class radioenhancer NBTXR3 in pancreatic ductal...

Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 + anti-PD-1 produced 63-day median survival in a genetic pancreatic cancer mouse model, in which mice develop their own pancreatic cancer and have an intact immune system. Historically, 42-days is the median survival produced by a 4-drug...

ImmunityBio Inc (NASDAQ: IBRX) has revealed early results from its Phase 2 metastatic pancreatic cancer trial (QUILT 88), showing that patients' overall survival rate doubled compared to the historical survival rate.  Phase 2 evaluates the comparative efficacy and overall...

Recently listed HCW Biologics Inc (NASDAQ: HCWB) shares almost doubled during premarket Thursday, after FDA signed off Phase 1b trial of its lead candidate in pancreatic cancer. The drug candidate, HCW9218, is an injectable, fusion protein complex designed to drive bifunctional...

Rafael Holdings Inc's (NYSE: RFL) Rafael Pharmaceuticals Inc announced that the AVENGER 500 Phase 3 trial for CPI-613 (devimistat) did not meet its primary endpoint of significant improvement in overall survival in pancreatic cancer patients. Data from 528 patients...

Novocure Ltd (NASDAQ: NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY) to develop Tumor Treating Fields (TTFields) together with Roche's atezolizumab in metastatic pancreatic ductal adenocarcinoma (mPDAC). The phase 2...

The FDA has granted a new 510(k) clearance to RenovoRx Inc's (NASDAQ: RNXT) RenovoCath Delivery System.  The RenovoCath Delivery System is the device component of the Company's initial product, RenovoGem.  The drug/device combination used in RenovoRx'...

The FDA has granted Orphan Drug Designation to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for pancreatic cancer.  LP-184 is a small molecule drug candidate and next-generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain...

XOMA Corporation (NASDAQ: XOMA) stock is trading higher during the morning session on robust volume after the FDA granted an Orphan drug tag to NIS793 for pancreatic cancer. Under the terms of the 2015 agreement between XOMA and Novartis AG (NYSE: AG), XOMA can earn up to...

The FDA has granted Orphan Drug Designation to Novartis AG's (NYSE: NVS) NIS793 in combination with standard of care chemotherapy to treat pancreatic cancer. NIS793 is a fully human anti-TGF-β IgG2 monoclonal antibody designed to inhibit the TGF-β pathway in tumor...